In a report released on April 2, Michael Cherny from Leerink Partners maintained a Buy rating on McKesson (MCK – Research Report), with a price ...

Leerink Partners analyst Faisal Khurshid reiterated a Hold rating on Nurix Therapeutics (NRIX – Research Report) on April 2. The company’s ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Biotech stocks toppled early Thursday after Trump announced broad global tariffs, including a 20% tariff on goods from Europe ...

Fintel reports that on April 2, 2025, Leerink Partners upgraded their outlook for Compass Therapeutics (NasdaqCM:CMPX) from Market Perform to Outperform. Analyst Price Forecast Suggests 419.11% Upside ...

Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector ...

Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are ...

AirSculpt Technologies (NASDAQ:AIRS – Get Free Report) had its price target decreased by equities research analysts at Leerink Partners from $6.50 to $2.50 in a research note issued to investors on ...

Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) had its price objective dropped by Leerink Partners from $19.00 to $18.00 ...

and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that its management will participate in the Leerink Partners Global Healthcare Conference 2025, taking place ...

Trump has repeatedly called April 2 “Liberation Day,” alluding to a more sweeping and aggressive set of tariffs. Leerink Partners analysts said that the risks from Trump’s tariffs on the biopharma ...

will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Tuesday, March 11th, 2025 at 10:00AM Eastern Time. A live webcast of the event will be available on the ...